Litcius/Paper detail

Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial

Jawad Fares, Atique U. Ahmed, Ilya V. Ulasov, Adam M. Sonabend, Jason Miska, Catalina Lee-Chang, Irina V. Balyasnikova, James P. Chandler, Jana Portnow, Matthew C. Tate, Priya Kumthekar, Rimas V. Lukas, Sean Grimm, Ann K. Adams, Charles Hébert, Theresa V. Strong, Christina Amidei, Víctor A. Arrieta, Μαρκέλλα Ζαννίκου, Craig Horbinski, Hui Zhang, Kirsten B. Burdett, David T. Curiel, Sean Sachdev, Karen S. Aboody, Roger Stupp, Maciej S. Lesniak

2021The Lancet Oncology208 citationsDOIOpen Access PDF

Topics & Concepts

Oncolytic virusMedicineGliomaTemozolomideCohortRadiation therapyOncologyInternal medicineClinical trialPhases of clinical researchOncolytic adenovirusSurgeryCancer researchCancerVirus-based gene therapy researchMesenchymal stem cell researchPluripotent Stem Cells Research
Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial | Litcius